Compounds, compositions and associated methods comprising 3-aryl quinolines
US-9249103-B2 · Feb 2, 2016 · US
US10023538B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10023538-B2 |
| Application number | US-201715440458-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 23, 2017 |
| Priority date | Jan 13, 2012 |
| Publication date | Jul 17, 2018 |
| Grant date | Jul 17, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.
Opening claim text (preview).
The invention claimed is: 1. A compound with the structure of Formula (II) wherein X 1 , X 2 , X 3 , X 4 , and X 5 are independently selected from of H, halo, alkoxy, ether, alkyl, substituted alkyl, alkyl ether, haloalkyl, haloalkyl ether, aryl, substituted aryl, aryl ether, substituted aryl ether, aryl amine, 5-member heterocycle, 6-member heterocycle, amino, benzylic amide, cyano, morpholinyl, N-ethyl morpholinyl, or carboxyl; and R 1 is selected from N—N-diethylpropanamino, N-isobutylpropanamino, N-isobutylpropanamino, N—N-diethylpropanamino, and 2-(2-piperidinyl) ethyl; or R 1 is N—N-diethyl-(4-methyl) butanamino and X 3 is OCF 3 . 2. The compound of claim 1 wherein the compound has a structure selected from: 3. A pharmaceutical composition comprising an effective amount of the compound of claim 1 . 4. A method of treating a parasitic infection in a subject, the method comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 3 to the subject. 5. The method of claim 4 wherein the pharmaceutical composition is administered orally, subcutaneously, intravenously or intramuscularly. 6. The method of claim 4 wherein the parasitic infection is a Plasmodium infection. 7. The method of claim 6 wherein the Plasmodium infection comprises an infection with a plasmodium strain resistant to one or more of the following classes of compounds: quinine, mefloquine, chloroquine, or atovaquone. 8. The method of claim 6 wherein the Plasmodium strain is selected from P. falciparum and P. vivax. 9. The compound of claim 1 , wherein X 1 , X 2 , X 4 , and X 5 are H and X 3 is OCF 3 .
Antimalarials · CPC title
Quinolines; Isoquinolines · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.